Face-to-face with anti-inflammatory therapy for rosacea

Experimental Dermatology

Volumn 23, Issue 6, 2014, Pages 379-381

  Salzer, Suzanna ^a   Ruzicka, Thomas ^a   Schauber, Jürgen ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cathelicidin; Doxycycline; Innate immunity; Protease activity; Rosacea

Indexed keywords

AZELAIC ACID; CATHELICIDIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; DOXYCYCLINE; ISOTRETINOIN; KALLIKREIN 5; METRONIDAZOLE; SERINE PROTEINASE; ANTIINFLAMMATORY AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; DISEASE ACTIVITY; DISEASE COURSE; EXPERIMENTAL THERAPY; HUMAN; INFLAMMATION; INNATE IMMUNITY; PROTEIN DEGRADATION; ROSACEA; THERAPY EFFECT; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANTI-INFLAMMATORY AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; HUMANS; IMMUNITY, INNATE; ROSACEA;

EID: 84901480632     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/exd.12401     Document Type: Article

References (35)

1. Elewski B E, Draelos Z, Dréno B et al. J Eur Acad Dermatol Venereol 2011: 25: 88.
2. Powell F C. N Engl J Med 2005: 352: 793.
3. Crawford G H, Pelle M T, James W D. J Am Acad Dermatol 2004: 51: 327.
4. Coda A B, Hatta T, Miller J et al. J Am Acad Dermatol 2013: 69: 570-577.
5. Zhang J, Xu X, Rao N V et al. PLoS ONE 2011: 6: e16658.
6. Yamasaki K, Gallo R L. J Dermatol Sci 2009: 55: 77.
7. Schauber J, Gallo R L. J Allergy Clin Immunol 2008: 122: 261.
8. Zanetti M. J Leukoc Biol 2004: 75: 39.
9. Koczulla R, von Degenfeld G, Kupatt C et al. J Clin Invest 2003: 111: 1665.
10. Yamasaki K, Di Nardo A, Bardan A et al. Nat Med 2007: 13: 975.
11. Casas C, Paul C, Lahfa M et al. Exp Dermatol 2012: 21: 906-910.
12. Borkowski A W, Gallo R L. J Invest Dermatol 2011: 131: 285.
13. Kanada K N, Nakatsuji T, Gallo R L. J Invest Dermatol 2012: 132: 1435-1442.
14. Nijnik A, Hancock R E. Curr Opin Hematol 2009: 16: 41-47.
15. Morizane S, Gallo R L. J Dermatol 2012: 39: 225-230.
16. Kahlenberg J M, Kaplan M J. J Immunol 2013: 191: 4895-4901.
17. Reinholz M, Ruzicka T, Schauber J. Ann Dermatol 2012: 24: 126-135.
18. Yamasaki K, Schauber J, Coda A et al. FASEB J 2006: 20: 2068.
19. Yamasaki K, Gallo R L. J Investig Dermatol Symp Proc 2011: 15: 12-15.
20. Ramos R, Silva J P, Rodrigues A C et al. Peptides 2011: 31: 1469.
21. Reinholz M, Tietze J K, Kilian K et al. J Dtsch Dermatol Ges 2013: 11: 768-780; 768-79.
22. Jones D A. J Clin Aesthet Dermatol 2009: 2: 26-30.
23. Narayanan S, Hünerbein A, Getie M et al. J Pharm Pharmacol 2007: 59: 1125-1130.
24. Briganti S, Flori E, Mastrofrancesco A et al. Exp Dermatol 2013: 22: 41-47.
25. Zheng Y, Niyonsaba F, Ushio H et al. Br J Dermatol 2007: 157: 1124-1131.
26. Korting H C. J Eur Acad Dermatol Venereol 2009: 23: 876-882.
27. Yamasaki K, Kanada K, Macleod D T et al. J Invest Dermatol 2011: 131: 688-697.
28. Fallen R S, Gooderham M. Skin Therapy Lett 2012: 17: 1-4.
29. Gollnick H, Blume-Peytavi U, Szabó E L et al. J Dtsch Dermatol Ges 2010: 8: 505-515.
30. Morizane S, Yamasaki K, Kabigting F D et al. J Invest Dermatol 2010: 130: 1297-1306.
31. Liu P T, Krutzik S R, Kim J et al. J Immunol 2005: 174: 2467-2470.
32. Dispenza M C, Wolpert E B, Gilliland K L et al. J Invest Dermatol 2012: 132: 2198-2205.
33. Tan X, Furio L, Reboud-Ravaux M et al. Bioorg Med Chem Lett 2013: 23: 4547-4551.
34. Tan X, Bertonati C, Qin L et al. Eur J Med Chem 2013: 70: 661-668.
35. Gessert C E, Bamford J T. Int J Dermatol 2003: 42: 444-448.